367 related articles for article (PubMed ID: 18954875)
1. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
Wade AG; Schlaepfer TE; Andersen HF; Kilts CD
J Psychiatr Res; 2009 Feb; 43(5):568-75. PubMed ID: 18954875
[TBL] [Abstract][Full Text] [Related]
2. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
Favré P
Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
[TBL] [Abstract][Full Text] [Related]
3. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
4. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
7. Superiority of escitalopram to paroxetine in the treatment of depression.
Kasper S; Baldwin DS; Larsson Lönn S; Boulenger JP
Eur Neuropsychopharmacol; 2009 Apr; 19(4):229-37. PubMed ID: 19185467
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
Colonna L; Andersen HF; Reines EH
Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
[TBL] [Abstract][Full Text] [Related]
9. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
Greist J; McNamara RK; Mallinckrodt CH; Rayamajhi JN; Raskin J
Clin Ther; 2004 Sep; 26(9):1446-55. PubMed ID: 15531007
[TBL] [Abstract][Full Text] [Related]
10. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
[TBL] [Abstract][Full Text] [Related]
11. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder.
Demyttenaere K; Andersen HF; Reines EH
Int Clin Psychopharmacol; 2008 Sep; 23(5):276-86. PubMed ID: 18703937
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
Chauvet-Gélinier JC
Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
[TBL] [Abstract][Full Text] [Related]
14. [Severe forms of depression: the efficacy of escitalopram].
Spadone C
Encephale; 2009 Apr; 35(2):152-9. PubMed ID: 19393384
[TBL] [Abstract][Full Text] [Related]
15. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database.
Baldwin DS; Stein DJ; Dolberg OT; Bandelow B
Hum Psychopharmacol; 2009 Jun; 24(4):269-75. PubMed ID: 19334042
[TBL] [Abstract][Full Text] [Related]
16. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
[TBL] [Abstract][Full Text] [Related]
17. Use of effect size to determine optimal dose of duloxetine in major depressive disorder.
Pritchett YL; Marciniak MD; Corey-Lisle PK; Berzon RA; Desaiah D; Detke MJ
J Psychiatr Res; 2007; 41(3-4):311-8. PubMed ID: 16934840
[TBL] [Abstract][Full Text] [Related]
18. Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: a double-blind, randomised, sham-controlled trial.
Bretlau LG; Lunde M; Lindberg L; Undén M; Dissing S; Bech P
Pharmacopsychiatry; 2008 Mar; 41(2):41-7. PubMed ID: 18311683
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder.
Perahia DG; Kajdasz DK; Walker DJ; Raskin J; Tylee A
Int J Clin Pract; 2006 May; 60(5):613-20. PubMed ID: 16700869
[TBL] [Abstract][Full Text] [Related]
20. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
Chokka P; Legault M
Depress Anxiety; 2008; 25(12):E173-81. PubMed ID: 19006260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
